Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma

Michael H Tomasson; Mahmoud Ali; Vanessa De Oliveira; Qian Xiao; Yogesh Jethava; Fenghuang Zhan; Adam M Fitzsimmons; Melissa L Bates

doi:10.3390/ijms19113621

Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma

Int J Mol Sci. 2018 Nov 16;19(11):3621. doi: 10.3390/ijms19113621.

Authors

Michael H Tomasson^{1

2}, Mahmoud Ali^{3

4}, Vanessa De Oliveira^{5

6}, Qian Xiao⁷, Yogesh Jethava^{8

9}, Fenghuang Zhan^{10

11}, Adam M Fitzsimmons¹², Melissa L Bates^{13

14

15}

Affiliations

¹ Department of Internal Medicine, Hematology, Oncology, and Bone Marrow Transplant Division, University of Iowa, Iowa City, IA 52242, USA. michael-tomasson@uiowa.edu.
² Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA. michael-tomasson@uiowa.edu.
³ Department of Internal Medicine, Hematology, Oncology, and Bone Marrow Transplant Division, University of Iowa, Iowa City, IA 52242, USA. Mahmoud-ali@uiowa.edu.
⁴ Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA. Mahmoud-ali@uiowa.edu.
⁵ Department of Internal Medicine, Hematology, Oncology, and Bone Marrow Transplant Division, University of Iowa, Iowa City, IA 52242, USA. vanessa-deoliveira@uiowa.edu.
⁶ Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA. vanessa-deoliveira@uiowa.edu.
⁷ Department of Health Human Physiology, University of Iowa, Iowa City, IA 52242, USA. qian-xiao@uiowa.edu.
⁸ Department of Internal Medicine, Hematology, Oncology, and Bone Marrow Transplant Division, University of Iowa, Iowa City, IA 52242, USA. yogesh-jethava@uiowa.edu.
⁹ Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA. yogesh-jethava@uiowa.edu.
¹⁰ Department of Internal Medicine, Hematology, Oncology, and Bone Marrow Transplant Division, University of Iowa, Iowa City, IA 52242, USA. Fenghuang-Zhan@uiowa.edu.
¹¹ Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA. Fenghuang-Zhan@uiowa.edu.
¹² Graduate Program in Molecular Medicine, University of Iowa, Iowa City, IA 52242, USA. adam-fitzsimmons@uiowa.edu.
¹³ Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA. melissa-bates@uiowa.edu.
¹⁴ Department of Health Human Physiology, University of Iowa, Iowa City, IA 52242, USA. melissa-bates@uiowa.edu.
¹⁵ Stead Family Department of Pediatrics, University of Iowa, Iowa, IA 52242, USA. melissa-bates@uiowa.edu.

Abstract

Multiple myeloma is an invariably fatal cancer of plasma cells. Despite tremendous advances in treatment, this malignancy remains incurable in most individuals. We postulate that strategies aimed at prevention have the potential to be more effective in preventing myeloma-related death than additional pharmaceutical strategies aimed at treating advanced disease. Here, we present a rationale for the development of prevention therapy and highlight potential target areas of study.

Keywords: monoclonal gammopathy of undetermined significance; multiple myeloma; plasma cell disease; prevention; therapy.

Publication types

Review

MeSH terms

Disease Progression*
Humans
Monoclonal Gammopathy of Undetermined Significance / genetics
Monoclonal Gammopathy of Undetermined Significance / pathology*
Multiple Myeloma / genetics
Multiple Myeloma / pathology*
Multiple Myeloma / prevention & control*
Multiple Myeloma / therapy
Mutation / genetics
Risk Factors

Abstract

Publication types

MeSH terms

Grants and funding